PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocyt...

Full description

Bibliographic Details
Main Authors: Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD
Format: Article
Language:English
Published: Elsevier 2016-10-01
Series:JACC: Basic to Translational Science
Subjects:
familial hypercholesterolemia
LDL receptor
lipoprotein(a)
PCSK9
primary human hepatocytes
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X16300675

Internet

http://www.sciencedirect.com/science/article/pii/S2452302X16300675

Similar Items